The cost of relapse and the predictors of relapse in the treatment of schizophrenia
Tóm tắt
To assess the direct cost of relapse and the predictors of relapse during the treatment of patients with schizophrenia in the United States. Data were drawn from a prospective, observational, noninterventional study of schizophrenia in the United States (US-SCAP) conducted between 7/1997 and 9/2003. Patients with and without relapse in the prior 6 months were compared on total direct mental health costs and cost components in the following year using propensity score matching method. Baseline predictors of subsequent relapse were also assessed. Of 1,557 participants with eligible data, 310 (20%) relapsed during the 6 months prior to the 1-year study period. Costs for patients with prior relapse were about 3 times the costs for patients without prior relapse. Relapse was associated with higher costs for inpatient services as well as for outpatient services and medication. Patients with prior relapse were younger and had onset of illness at earlier ages, poorer medication adherence, more severe symptoms, a higher prevalence of substance use disorder, and worse functional status. Inpatient costs for patients with a relapse during both the prior 6 months and the follow-up year were 5 times the costs for patients with relapse during the follow-up year only. Prior relapse was a robust predictor of subsequent relapse, above and beyond information about patients' functioning and symptom levels. Despite the historical decline in utilization of psychiatric inpatient services, relapse remains an important predictor of subsequent relapse and treatment costs for persons with schizophrenia.
Tài liệu tham khảo
Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophr Bull. 1995, 21 (3): 419-429.
Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004, 161 (1): 692-699. 10.1176/appi.ajp.161.4.692.
Almond S, Knapp M, Francois C, Toumi M, Brugha T: Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004, 184: 346-351. 10.1192/bjp.184.4.346.
Svarstad BL, Shireman TI, Sweeney JK: Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001, 52 (6): 805-811. 10.1176/appi.ps.52.6.805.
Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J: Cost of disorders of the brain in Europe. Eur J Neurol. 2005, 12 (Suppl 1): 1-27. 10.1111/j.1468-1331.2005.01202.x.
Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002, 40 (8): 630-639. 10.1097/00005650-200208000-00002.
Weiden PJ: Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry. 2007, 68 (Suppl 14): 14-19.
Marcus SC, Olfson M: Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008, 34 (1): 173-180. 10.1093/schbul/sbm061.
Sun SX, Liu GG, Christensen DB, Fu AZ: Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007, 23 (10): 2305-2312. 10.1185/030079907X226050.
Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006, 67 (3): 453-460. 10.4088/JCP.v67n0317.
Salkever DS, Slade EP, Karakus MC: Employment retention by persons with schizophrenia employed in non-assisted jobs. J Rehabil. 2003, 69 (4): 19-26.
Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, Russo PA, Crown WH: The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Schizophr Bull. 2003, 29 (2): 247-256.
Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13 (2): 261-276.
Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979, 134: 382-389. 10.1192/bjp.134.4.382.
Ware JE, Kosinski M, Keller SD: How to Score the SF-12? Physical and Mental Health Summary Scales. 1998, Lincoln, RI: QualityMetric, 3
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J: CATIE Study Investigators: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006, 163 (12): 2080-2089. 10.1176/appi.ajp.163.12.2080.
Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R: Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health. 2006, 9 (2): 77-89. 10.1111/j.1524-4733.2006.00083.x.
Hsiao WC, Braun P, Dunn D, Becker ER: Resource-based relative values. An overview. JAMA. 1988, 260 (16): 2347-2353. 10.1001/jama.260.16.2347.
Vaul JH: DRG benchmarking study establishes national coding norms. Healthc Financ Manage. 1998, 52 (52): 54-
D'Agostino RB: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998, 17 (19): 2265-2281. 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B.
Weiden PJ, Kozma C, Grogg A, Locklear J: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004, 55 (8): 886-891. 10.1176/appi.ps.55.8.886.
Law MR, Soumerai SB, Ross-Degnan D, Adams AS: A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008, 69 (1): 47-53. 10.4088/JCP.v69n0107.
Welch WP: Medicare capitation payments to HMOs in light of regression towards the mean in health care costs. Advances in Health Economics and Health Services Research. Edited by: Scheffler RM, Rossiter LF. 1985, Greenwich, CT: JAI Press, 6:
Wrobel MV, Doshi J, Stuart BC, Briesacher B: Predictability of prescription drug expenditures for Medicare beneficiaries. Health Care Financ Rev. 2003, 25 (2): 37-46.
Newhouse JP, Manning WG, Keeler EB, Sloss EM: Adjusting capitation rates using objective health measures and prior utilization. Health Care Financ Rev. 1989, 10 (3): 41-54.
Donohue J: Mental health in the Medicare Part D drug benefit: a new regulatory model?. Health Aff (Millwood). 2006, 25 (3): 707-719. 10.1377/hlthaff.25.3.707.
Salkever DS, Slade EP, Karakus M, Palmer L, Russo PA: Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables. J Nerv Ment Dis. 2004, 192 (2): 119-128. 10.1097/01.nmd.0000110283.89270.23.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/10/2/prepub